Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis
Jean‐Yves Reginster(King Saud University), Cheryl Keech, Suresh Siddhanti(Amgen (United States)), J Adachi, Yang Qu(University of New Brunswick)
Open Repository and Bibliography (University of Liège)
November 1, 2003
Cited by 0
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
|New England Journal of Medicine|2012|361